Free Trial

Agios Pharmaceuticals Q2 2024 Earnings Report

Agios Pharmaceuticals logo
$42.50 +0.54 (+1.29%)
(As of 09:00 AM ET)

Agios Pharmaceuticals Earnings Headlines

Q1 EPS Forecast for Agios Pharmaceuticals Lowered by Analyst
Forced out of retirement by these trades
You know, I never really intended to get in front of a camera and tell folks about a new market paradigm that I discovered. Even though I have a bright and shiny “resume,” I thought I’d left investing behind forever. And I was more than happy to be a stay-at-home dad… But then I discovered Gamma Pockets… and everything changed
See More Agios Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Agios Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Agios Pharmaceuticals and other key companies, straight to your email.

About Agios Pharmaceuticals

Agios Pharmaceuticals (NASDAQ:AGIO), a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

View Agios Pharmaceuticals Profile

More Earnings Resources from MarketBeat

Upcoming Earnings